A clinical study to evaluate the preventive effect of denosumab(Pralia) on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 29 Jun 2017 Status changed from recruiting to discontinued.
- 17 Sep 2014 New trial record